Ergotamin

Ergotamin
Data klinis
Nama dagangCafergot (with caffeine), Ergomar, others
Nama lain2'-Methyl-5'α-benzyl-12'-hydroxy-3',6',18-trioxoergotaman; 9,10α-Dihydro-12'-hydroxy-2'-methyl-5'α-(phenylmethyl)ergotaman-3',6',18-trione
AHFS/Drugs.commonograph
Rute
pemberian		Oral
Kode ATC
Status hukum
Status hukum
Data farmakokinetika
BioavailabilitasIntravenous: 100%,[1]
Intramuscular: 47%,[2]
Oral: <1%[3] (Enhanced by co-administration of caffeine[1])
MetabolismeHepatic[2]
Waktu paruh eliminasi2 hours[2]
Ekskresi90% biliary[2]
Pengenal
  • (6aR,9R)-N-((2R,5S,10aS,10bS)-5-Benzyl-10b-hydroxy-2-methyl-3,6-dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
Nomor CAS
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
Ligan PDB
CompTox Dashboard (EPA)
ECHA InfoCard100.003.658 Sunting di Wikidata
Data sifat kimia dan fisik
RumusC33H35N5O5
Massa molar581,67 g·mol−1
Model 3D (JSmol)
  • C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C
  • InChI=1S/C33H35N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,15,17,21,25-27,34,42H,7,12-14,16,18H2,1-2H3,(H,35,39)/t21-,25-,26+,27+,32-,33+/m1/s1 checkY
  • Key:XCGSFFUVFURLIX-VFGNJEKYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Ergotamin adalah obat yang digunakan untuk meredakan atau mencegah migrain. Obat ergotamin biasanya dapat ditemukan dalam produk obat yang dikombinasikan dengan kafein. Obat ergotamin merupakan vasokonstriktor agonis adrenergik selektif alfa-1.[4][5]

Referensi

  1. ^ a b Sanders SW, Haering N, Mosberg H, Jaeger H (1986). "Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing". European Journal of Clinical Pharmacology. 30 (3): 331–334. doi:10.1007/BF00541538. PMID 3732370. S2CID 37538721.
  2. ^ a b c d Tfelt-Hansen P, Johnson ES (1993). "Ergotamine". Dalam Olesen J, Tfelt-Hansen P, Welch KM (ed.). The Headaches. New York: Raven Press. hlm. 313–22.
  3. ^ Ibraheem JJ, Paalzow L, Tfelt-Hansen P (December 1983). "Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers". British Journal of Clinical Pharmacology. 16 (6): 695–699. doi:10.1111/j.1365-2125.1983.tb02243.x. PMC 1428366. PMID 6419759.
  4. ^ "Ergotamine-Caffeine Oral: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD". www.webmd.com (dalam bahasa Inggris). Diakses tanggal 2023-06-20.
  5. ^ "Ergotamine". go.drugbank.com. Diakses tanggal 2023-06-20.
Ikon rintisan

Artikel bertopik farmasi ini adalah sebuah rintisan. Anda dapat membantu Wikipedia dengan mengembangkannya.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.